Efficacy and safety of mirabegron after posterior urethral valve ablation
Omar Mohamed, Mohamed Ahmed Hassan El-Gelany, Atef Fathi, Ahmad AbolyosrAbstract
Background:
Valve bladder syndrome is a persistent bladder dysfunction after posterior urethral valve (PUV) ablation, causing poor bladder compliance and possible renal deterioration. Mirabegron may improve bladder function with fewer side effects than anticholinergic therapy, but evidence after PUV ablation is limited.
Aim:
To evaluate efficacy and safety of mirabegron after PUV ablation.
Patients and Methods:
This cross-sectional study included 15 children older than 3 years who underwent PUV ablation and received mirabegron (0.5–1 mg/kg/day). Patients with residual valves, previous urinary diversion, or associated neurogenic bladder were excluded. Baseline assessment included clinical examination, urine analysis, serum creatinine, renal/bladder ultrasound, voiding cystourethrogram, and SWRD score evaluation. Patients were followed for 6 months with clinical, laboratory, and radiological monitoring to evaluate treatment efficacy and safety.
Results:
The mean age was 7.21 ± 2.93 years, with mean weight 19.55 ± 7.69 kg and height 115.89 ± 19.27 cm. After 6 months of mirabegron therapy, febrile urinary tract infection episodes decreased significantly (
Conclusion:
Mirabegron appears to be a safe and effective option for bladder dysfunction after PUV ablation, improving urinary symptoms, renal parameters, and bladder status. Larger studies with longer follow-up are needed to confirm long-term benefits.